On Monday, Amedica Corporation (NASDAQ:AMDA)’s shares declined -5.75% to $0.412.
Amedica Corporation (AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, announced its expected participation in the following investor conference:
2015 Ladenburg Thalmann Healthcare Conference, Tuesday, September 29, 2015, 11:30 AM Eastern Time, New York, NY.
Amedica Corporation, a commercial-stage biomaterial company, develops, manufactures, and sells a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America. It offers Valeo silicon nitride interbody spinal fusion devices for use in the cervical and thoracolumbar areas of the spine; and a line of non-silicon nitride spinal fusion products.
Thomson Reuters Corp (NYSE:TRI)’s shares gained 1.60% to $40.57.
Thomson Reuters introduced its Checkpoint Learning Tax Fundamentals Certificate Program recently to provide practitioners with foundational knowledge in a broad range of tax topics and assists them develop overall tax competency.
The Tax Fundamentals Certificate Program provides practitioners with the basic knowledge and tools they need to understand and confidently expand their practices to tax planning, compliance with tax return preparation, and reporting requirements for individual, partnership, C corporation, and S corporation taxation.
Individuals who are new to the profession or are returning to the profession after an extended break, in addition to organizations that employ such individuals, will benefit from this program by focusing on the foundational knowledge needed to prepare Forms 1040, 1065, 1120, and 1120-S, together with explanations and tips for concluding these and other related tax forms and plans.
Thomson Reuters Corporation provides intelligent information for businesses and professionals worldwide. The company sells electronic content and services to professionals primarily on a subscription basis.
At the end of Monday’s trade, Advanced Energy Industries, Inc. (NASDAQ:AEIS)‘s shares surged 1.11% to $25.48.
Advanced Energy Industries, Inc. (AEIS) declared a formalized capital deployment strategy. Over the past several quarters, Advanced Energy has embarked on a strategic transformation to build a strong model around its core precision power business. An integral part of this model is the company’s strong cash generating capabilities and current balance sheet. In keeping with the company’s overall objectives, the capital deployment strategy is centered on increasing shareholder value by investing in long-term growth opportunities and making distributions to shareholders.
Advanced Energy’s capital deployment strategy encompasses the following:
- organic investments to grow its market leadership in semiconductor applications, expand into industrial markets and enhance its geographic presence;
- acquisitions to enhance the company’s total addressable market with a particular focus on industrial products and applications;
- share repurchases to meaningfully reduce share count over time; and
- a more flexible capital structure that may comprise debt instruments to fund key investments.
Advanced Energy Industries, Inc., together with its auxiliaries, designs, manufactures, sells, and supports power conversion and control products that transform power into various usable forms. The company operates through two segments, Precision Power Products and Inverters.
Akebia Therapeutics Inc (NASDAQ:AKBA), ended its Monday’s trading session with -5.03% loss, and closed at $10.76.
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), recently declared three additions to its senior administration team: Teresa Compton, PhD joined Akebia as Senior Vice President and Chief Scientific Officer, Ramin Farzaneh-Far, MD as Vice President of Medical Research, and Ed Joyce as Vice President, Investor Relations and Corporate Communications.
Teresa Compton, PhD, brings to Akebia a wealth of expertise and a deep background as a successful scientist. Most recently, Dr. Compton was Vice President and Head of Translational Sciences at Biogen Idec. Proceeding to that, Dr. Compton was Executive Director at the Novartis Institutes for Biomedical Research. Additionally she spent 13 years on the faculty of the University of Wisconsin School of Medicine as Professor in the Oncology Department where she published over 75 research articles and was continuously funded by the National Institutes of Health during her academic tenure. Dr. Compton earned a PhD from the University of Tennessee in Cellular and Molecular Biology with postdoctoral research at New York University Medical Center and the Scripps Research Institute. She presently serves as Chair of the Scientific Advisory Board at the Morgridge Institute of Research at the University of Wisconsin, the Chancellor’s Executive Council at the University of Tennessee, and the Scientific Advisory Board of Molecules to Medicine Institute at the University of Massachusetts Amherst. Dr. Compton will report to John P. Butler, President and Chief Executive Officer.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is AKB-6548, an oral therapy which has accomplished a Phase 2b study for the treatment of anemia related to chronic kidney disease in non-dialysis patients, in addition to tested in a Phase 2 study for the treatment of anemia in patients undergoing dialysis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
